Navigation Links
NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate
Date:1/12/2010

italizations in high risk adults resulting in annual medicals costs exceeding $1 billion.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology.  The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches.  Novavax is committed to using its VLP technology to create country-specific vaccine solutions.  The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

Forward Looking Statement

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical trials and development of the seasonal influenza vaccine and other anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress the product candidate in preclinical or clinical trials; the
'/>"/>

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- Guggenheim Securities, the investment banking and capital markets ... veteran equity analyst Charles "Tony" Butler as a managing ... on the biotech/biopharma sector. " Tony Butler ... a broad network of relationships in his industry," said ... of Equities at Guggenheim Securities. "His insights will further ...
(Date:8/27/2014)... 27, 2014  ARCH Venture Partners, one of ... the development of seed and early-stage advanced technology ... closed with more than $400 million in subscriptions. ... subscription target by more than $150 million. ... strength and potential of our approach to finding ...
(Date:8/27/2014)... City, OR (PRWEB) August 27, 2014 ... Report, “Consolidation continues to reshape the look and feel ... nutrition. Consumer demand for higher-quality ingredients will push for ... North American market have experienced strong market growth in ... ethical attributes in their food and cosmetics to fit ...
(Date:8/26/2014)... -- NeuroSigma, Inc., a Los Angeles -based ... announced that it has filed a registration statement on ... relating to a proposed initial public offering of its ... and the price range for the proposed offering have ... act as the book-running manager for the proposed offering, ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... , , NEW YORK, Aug. 13 ... the second quarter ended June 30, 2009. , , Revenues ... in 2008. Net loss for the second quarter of 2009 was $103,330, ... Basic net loss per share for the second quarter of 2009 was $0.01, ...
... , , MANHATTAN, ... around the world hundreds of millions of dollars each year. , ... Hesse and Bob Rowland have been working to create new vaccines ... and its associated diseases continue to emerge around the world," Hesse ...
... FORT LAUDERDALE, Fla., Aug. 13 OmniComm Systems, Inc. ... capture (EDC) solutions for clinical trials, today announced that it ... Organization (CRO) to provide eClinical solutions for a pivotal Phase ... serve to establish the safety and efficacy of investigational new ...
Cached Biology Technology:Cadus Reports Second Quarter 2009 Results 2Cadus Reports Second Quarter 2009 Results 3Cadus Reports Second Quarter 2009 Results 4Cadus Reports Second Quarter 2009 Results 5K-State's Biosecurity Research Institute Gives Researchers the Tools Needed to Study Diseases That Cost Pig Producers Hundreds of Millions of Dollars Each Year 2K-State's Biosecurity Research Institute Gives Researchers the Tools Needed to Study Diseases That Cost Pig Producers Hundreds of Millions of Dollars Each Year 3Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study 2
(Date:8/27/2014)... that a deficiency in serotonin a chemical messenger ... depression. In the journal ACS Chemical Neuroscience , ... serotonin in their brains (and thus should have been ... , Donald Kuhn and colleagues at the John ... School of Medicine note that depression poses a major ...
(Date:8/27/2014)... have largely succeeded in sidelining the use of ... its potential contributions to Americans, health conditions. But ... best way to assuage the nation,s insatiable sweet ... & Engineering News (C&EN), the weekly news ... the article, Stephen Ritter, a senior correspondent at ...
(Date:8/27/2014)... can be weaned later with no negative effects on ... at the University,s Roseworthy campus, published in the journal ... for pig producers. It allows improvements in piglet health ... usually start their oestrous cycles again during lactation, only ... says Ms Alice Weaver, PhD candidate with the School ...
Breaking Biology News(10 mins):New study throws into question long-held belief about depression 2Piglet weaning age no bar to litter frequency 2
... identify new anti-cancer, anti-infection response control mechanism , ... de recherches cliniques de Montréal (IRCM), and his ... the prestigious journal Nature Immunology of Nature Publishing ... treatment of cancers and infectious diseases. Current treatments ...
... to clone human embryos from eggs that have been ... easier for scientists to create embryonic stem cell lines ... and sperm for infertile couples, the 21st annual conference ... heard today (Monday 20 June). , Until now, scientists ...
... the structure of a crucial human immune system molecule ... an upcoming issue of the journal Science, the protein ... 23 leucine-rich repeats (LRRs). , The structure reveals details ... essential step toward fully understanding the critical role this ...
Cached Biology News:Major breakthrough in the treatment of cancers and infectious diseases 2Scientists succeed in cloning human embryos from eggs matured in the lab 2Scientists succeed in cloning human embryos from eggs matured in the lab 3Scripps research scientists solve structure of a critical innate immune system protein 2Scripps research scientists solve structure of a critical innate immune system protein 3Scripps research scientists solve structure of a critical innate immune system protein 4